Alnylam, Cubist Say 90-Day Data Shows RSV Drug to Be Safe, Suggests Efficacy

The companies said that they plan to evaluate these and other data, including ones related to second-generation RSV agents, "to determine the optimal development strategy and specific plans for all RSV indications."

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.